A new drug may help treat and eventually eliminate sleeping sickness by improving adherence and accessibility to treatment.

New genetic data shows no meaningful overlap between vitamin B12 status determinants and Parkinson disease outcomes in clinical cohorts.

Rising vitamin K refusal rates correlated with later healthcare hesitancy, including higher likelihoods of refusing childhood immunizations.

Fenebrutinib significantly reduced the annualized relapse rate in patients with relapsing multiple sclerosis compared with teriflunomide.

The FDA expands Palynziq approval to include pediatric patients aged 12 years and older with phenylketonuria and uncontrolled blood Phe levels.

Based on current trends in cardiovascular health for women, cardiovascular risk and disease are projected to increase through 2050.

A meta-analysis shows GLP-1 RA therapy does not significantly lower vascular dementia events compared with placebo in high-risk patient groups.

Comorbid insomnia and sleep apnea with short sleep duration significantly increases the risk for incident hypertension in a general population.

Experts analyze the unique biomechanical risks for traumatic brain injury in winter sports following high-profile incidents at the 2026 Winter Olympics.

Higher functional independence scores correlate with a greater likelihood of returning home after inpatient traumatic brain injury care.

Desmoda oral solution is now FDA-approved for central diabetes insipidus, allowing clinicians to tailor dosing to individual water balance patterns.